Avalo Therapeutics (NASDAQ:AVTX) Insider Mittie Doyle Sells 679 Shares of Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) insider Mittie Doyle sold 679 shares of the business’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $20.00, for a total transaction of $13,580.00. Following the sale, the insider directly owned 51,776 shares of the company’s stock, valued at $1,035,520. This represents a 1.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mittie Doyle also recently made the following trade(s):

• On Monday, July 27th, Mittie Doyle sold 1,000 shares of Avalo Therapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $20,000.00.
• On Tuesday, June 23rd, Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock. The stock was sold at an average price of $18.00, for a total transaction of $26,100.00.

Avalo Therapeutics Price Performance

NASDAQ:AVTX opened at $18.95 on Wednesday. The firm has a market capitalization of $1.02 billion, a PE ratio of -4.34 and a beta of 0.78. Avalo Therapeutics, Inc. has a 12 month low of $8.65 and a 12 month high of $24.27. The business’s fifty day moving average price is $19.05 and its 200 day moving average price is $16.85.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). As a group, equities analysts anticipate that Avalo Therapeutics, Inc. will post -2.59 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AVTX. Geode Capital Management LLC increased its position in shares of Avalo Therapeutics by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock worth $552,000 after purchasing an additional 2,648 shares in the last quarter. Nantahala Capital Management LLC boosted its position in Avalo Therapeutics by 10.6% in the second quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company’s stock valued at $4,965,000 after buying an additional 95,000 shares in the last quarter. Bank of America Corp DE grew its stake in Avalo Therapeutics by 7,066.8% during the second quarter. Bank of America Corp DE now owns 406,571 shares of the company’s stock worth $2,029,000 after buying an additional 400,898 shares during the last quarter. Boothbay Fund Management LLC acquired a new stake in shares of Avalo Therapeutics during the second quarter worth approximately $56,000. Finally, Vanguard Group Inc. raised its stake in shares of Avalo Therapeutics by 314.9% in the third quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock valued at $8,803,000 after acquiring an additional 525,696 shares during the last quarter. Institutional investors own 87.06% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Wedbush dropped their price target on shares of Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a research note on Thursday, May 14th. Citigroup reiterated an “outperform” rating on shares of Avalo Therapeutics in a research note on Wednesday, May 6th. Leerink Partners initiated coverage on Avalo Therapeutics in a report on Monday, July 6th. They set an “outperform” rating and a $38.00 target price for the company. Mizuho upped their price objective on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the company an “outperform” rating in a research note on Thursday, May 14th. Finally, Guggenheim set a $48.00 target price on Avalo Therapeutics and gave the company a “buy” rating in a report on Friday, August 7th. Thirteen equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $45.10.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.